151 related articles for article (PubMed ID: 18059612)
1. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease.
Muoio DM; Koves TR
Appl Physiol Nutr Metab; 2007 Oct; 32(5):874-83. PubMed ID: 18059612
[TBL] [Abstract][Full Text] [Related]
2. Lipid-induced metabolic dysfunction in skeletal muscle.
Muoio DM; Koves TR
Novartis Found Symp; 2007; 286():24-38; discussion 38-46, 162-3, 196-203. PubMed ID: 18269172
[TBL] [Abstract][Full Text] [Related]
3. Regulation of energy metabolism by long-chain fatty acids.
Nakamura MT; Yudell BE; Loor JJ
Prog Lipid Res; 2014 Jan; 53():124-44. PubMed ID: 24362249
[TBL] [Abstract][Full Text] [Related]
4. [PPARs Mediate the Regulation of Energy Metabolism By Long-Chain Fatty Acids].
Yan Y; Wang ZB; Tang CK
Sheng Li Ke Xue Jin Zhan; 2016 Feb; 47(1):1-6. PubMed ID: 27424398
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
Smith AG; Muscat GE
Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
[TBL] [Abstract][Full Text] [Related]
6. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists.
Fuster G; Busquets S; Ametller E; Olivan M; Almendro V; de Oliveira CC; Figueras M; López-Soriano FJ; Argilés JM
Cancer Res; 2007 Jul; 67(13):6512-9. PubMed ID: 17616713
[TBL] [Abstract][Full Text] [Related]
7. The effect of exercise on epigenetic modifications of PGC1: The impact on type 2 diabetes.
Santos JM; Tewari S; Benite-Ribeiro SA
Med Hypotheses; 2014 Jun; 82(6):748-53. PubMed ID: 24703492
[TBL] [Abstract][Full Text] [Related]
8. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.
Turner N; Bruce CR; Beale SM; Hoehn KL; So T; Rolph MS; Cooney GJ
Diabetes; 2007 Aug; 56(8):2085-92. PubMed ID: 17519422
[TBL] [Abstract][Full Text] [Related]
9. Putative PPAR target genes express highly in skeletal muscle of insulin-resistant MetS model SHR/NDmc-cp rats.
Hariya N; Miyake K; Kubota T; Goda T; Mochizuki K
J Nutr Sci Vitaminol (Tokyo); 2015; 61(1):28-36. PubMed ID: 25994137
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD.
Remels AH; Schrauwen P; Broekhuizen R; Willems J; Kersten S; Gosker HR; Schols AM
Eur Respir J; 2007 Aug; 30(2):245-52. PubMed ID: 17459894
[TBL] [Abstract][Full Text] [Related]
11. Enhancing fatty acid oxidation negatively regulates PPARs signaling in the heart.
Liu Z; Ding J; McMillen TS; Villet O; Tian R; Shao D
J Mol Cell Cardiol; 2020 Sep; 146():1-11. PubMed ID: 32592696
[TBL] [Abstract][Full Text] [Related]
12. Nitrate enhances skeletal muscle fatty acid oxidation via a nitric oxide-cGMP-PPAR-mediated mechanism.
Ashmore T; Roberts LD; Morash AJ; Kotwica AO; Finnerty J; West JA; Murfitt SA; Fernandez BO; Branco C; Cowburn AS; Clarke K; Johnson RS; Feelisch M; Griffin JL; Murray AJ
BMC Biol; 2015 Dec; 13():110. PubMed ID: 26694920
[TBL] [Abstract][Full Text] [Related]
13. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J
J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
[TBL] [Abstract][Full Text] [Related]
15. Deletion of nuclear factor-κB p50 upregulates fatty acid utilization and contributes to an anti-obesity and high-endurance phenotype in mice.
Minegishi Y; Haramizu S; Misawa K; Shimotoyodome A; Hase T; Murase T
Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E523-33. PubMed ID: 26173458
[TBL] [Abstract][Full Text] [Related]
16. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder.
Barone R; Rizzo R; Tabbì G; Malaguarnera M; Frye RE; Bastin J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995737
[TBL] [Abstract][Full Text] [Related]
17. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
[TBL] [Abstract][Full Text] [Related]
18. Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment?
Grimaldi PA
Biochimie; 2005 Jan; 87(1):5-8. PubMed ID: 15733729
[TBL] [Abstract][Full Text] [Related]
19. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
Luquet S; Lopez-Soriano J; Holst D; Gaudel C; Jehl-Pietri C; Fredenrich A; Grimaldi PA
Biochimie; 2004 Nov; 86(11):833-7. PubMed ID: 15589693
[TBL] [Abstract][Full Text] [Related]
20. Childhood obesity and insulin resistance in a Yucatan mini-piglet model: putative roles of IGF-1 and muscle PPARs in adipose tissue activity and development.
Sébert SP; Lecannu G; Kozlowski F; Siliart B; Bard JM; Krempf M; Champ MM
Int J Obes (Lond); 2005 Mar; 29(3):324-33. PubMed ID: 15672115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
